- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00231764
MMF, Daclizumab and Corticosteroids as Mainstay Immunosuppression in Renal Transplant Patients
Evaluating Safety and Efficacy of MMF, Daclizumab and Corticosteroids as Mainstay Immunosuppression in Combination With Low-Dose CsA, Tac or Sir in Comparison to Current Standard Immunosuppression (MMF, CsA and Corticosteroids) in Renal Tx
Study Overview
Detailed Description
The purpose of the SYMPHONY study is to compare four different immunosuppressive regimens. They are each given for one year. The following four combinations are tested in four groups of patients:
- Group A: Cyclosporine in a normal dosage, mycophenolate mofetil (MMF) and corticosteroids
- Group B: Daclizumab in the first two months after transplantation, cyclosporine in a lower dosage compared to group A, mycophenolate mofetil (MMF) and corticosteroids
- Group C: Daclizumab in the first two months after transplantation, tacrolimus in low dosage, mycophenolate mofetil (MMF) and corticosteroids
- Group D: Daclizumab in the first two months after transplantation, sirolimus in a low dosage, mycophenolate mofetil (MMF) and corticosteroids.
All drugs of the four immunosuppressive regimes are approved by the Health Authorities in the participating country for use in kidney transplantation. The regimen administered to the patients in Group A represents a standard treatment, currently given with success to many transplant patients in a number of countries in the world. The treatments in Groups B, C and D are experimental in the sense that either the doses administered are lower than the ones used before and/or the combination of drugs is experimental. Nevertheless, there are results of scientific studies indicating that they are all effective alternatives and that they might have advantages compared to the standard immunosuppressive regimen, in particular as far as their safety (side effects, long-term toxicity) is concerned. However, from the previous clinical experience, it is not yet clear which regimen offers the most advantages for the patients. To find this out, in SYMPHONY the four regimens are administered to the four groups of patients (A-D) and the results in the different groups will be compared.
Study Type
Enrollment
Phase
- Phase 4
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female patients between 18 - 75 years
- Recipients of single-organ renal primary allograft or second renal transplants (provided that the previous graft was not lost from acute rejection within the first year) from living or cadaver donors
- Patients who provide written informed consent.
Exclusion Criteria:
- PRA > 20% within 6 months prior to enrollment
- Cold ischemia time > 30 hours
- Previous treatment with daclizumab
- History of malignancy (except localized skin cancer)
- Active peptic ulcer disease.
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
GFR calculated from the serum creatinine with the Cockcroft-Gault formula at 12 months posttransplantation
|
Secondary Outcome Measures
Outcome Measure |
---|
Acute rejection rate at 6 and 12 months, patient and graft survival rates at 12 months
|
Treatment failure during the first twelve months
|
Time to first acute rejection
|
Patient and graft survival at 6 and 12 months posttransplant
|
Calculated GFR using the Cockcroft-Gault formula during the study and measured GFR at month 12
|
Incidence of Delayed Graft Function (DGF)
|
Safety Parameters:
|
Clinical assessments, vital signs, laboratory analyses, adverse events, opportunistic infections, malignancies, and deaths
|
Incidence of failure to achieve primary closure of transplant surgical wound at 2 weeks
|
Incidence of lymphocele requiring intervention in the first 6 months posttransplant
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Henrik Ekberg, Prof., Malmo University Hospital, Malmö, Sweden
- Study Chair: Philip Halloran, Prof., University of Alberta, Edmonton, Canada
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SYMPHONY
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Transplantation
-
Astellas Pharma IncAstellas Pharma Europe B.V.CompletedKidney Transplantation | Renal Transplantation | Transplantation, Kidney | Grafting, Kidney | Transplantation, RenalBelgium, Germany, Spain, Sweden, Italy, Switzerland, United Kingdom, Austria, France, Poland, Czech Republic, Netherlands
-
Bristol-Myers SquibbCompletedKidney Transplantation: Transplantation, Kidney
-
Nantes University HospitalTerminated
-
Hospices Civils de LyonCompletedKidney Transplantation | Pancreas-kidney TransplantationFrance
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationCzechia, France, Italy, Poland, United Kingdom
-
The Hospital for Sick ChildrenCompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationCanada
-
Astellas Pharma Europe Ltd.TerminatedLiver Transplantation | Kidney Transplantation | Heart TransplantationBelgium, France, Germany, Poland, Spain, United Kingdom
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationSpain, Australia, France, Germany, Canada, Italy, United Kingdom, Belgium, South Africa, Switzerland, Sweden, United States, Austria, Brazil, Czechia, Denmark, Finland, Hungary, Ireland, Mexico, Netherlands, New Zealand, Poland
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationBelgium, France, Germany, Poland, Spain, United Kingdom
-
Medical University of ViennaUnknownKidney Function After Transplantation | Outcome After Kidney Transplantation
Clinical Trials on daclizumab
-
BiogenAbbVieTerminatedMultiple Sclerosis | Relapsing-Remitting Multiple SclerosisUnited States, Denmark, Italy, United Kingdom, Czechia, Canada, Hungary, Spain, Australia, Israel, Georgia, Serbia, Russian Federation, Ukraine, India, Poland, Brazil, France, Argentina, Germany, Greece, Ireland, Mexico, Moldova, Republic... and more
-
BiogenAbbVieCompletedRelapsing-Remitting Multiple SclerosisCzech Republic, Poland, Russian Federation, United Kingdom, Hungary, Ukraine, Germany, India
-
BiogenAbbVieCompletedRelapsing-Remitting Multiple SclerosisCzech Republic, Poland, Russian Federation, United Kingdom, Hungary, Ukraine, Germany, India
-
BiogenAbbVieCompletedRelapsing-Remitting Multiple SclerosisGermany, Hungary, Czechia, Russian Federation, India, Poland, Ukraine, United Kingdom
-
King's College Hospital NHS TrustCompletedHTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL)United Kingdom
-
National Cancer Institute (NCI)TerminatedHodgkin Disease | Hodgkin LymphomaUnited States
-
National Cancer Institute (NCI)Completed
-
University of IowaCompletedGraft vs Host DiseaseUnited States